Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL) will present new preclinical data for its HER2-selective inhibitor NVL-330 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025 in Boston.

The poster, titled “Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor” (Abstract No. B057), is authored by Yuting Sun and colleagues and will be presented during Poster Session B on Friday, October 24, 2025, 12:30–4:00 p.m. ET in Exhibit Hall D. Yuting Sun is listed as presenter and corresponding author.

CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation further characterizing the preclinical intracranial activity of its novel HER2-selective inhibitor, NVL-330, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston.

Details of the poster presentation are as follows:

Title: Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor
Abstract Number: B057
Authors: Yuting Sun*¹, Kristin L. Andrews¹, Anupong Tangpeerachaikul¹, Michael J. Walsh¹, Nancy E. Kohl², Joshua C. Horan¹, Henry E. Pelish¹
Session: Poster Session B
Session Date and Time: Friday, October 24, 2025, 12:30-4:00 p.m. ET
Location: Exhibit Hall D

*Presenter, corresponding author; ¹Nuvalent, Inc., Cambridge, MA, USA; ²Kohl Consulting, Wellesley, MA, USA

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-data-for-her2-selective-inhibitor-nvl-330-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-302582286.html

SOURCE Nuvalent, Inc.

FAQ

When will Nuvalent present preclinical NVL-330 data at AACR-NCI-EORTC 2025?

The poster will be presented on Friday, October 24, 2025, 12:30–4:00 p.m. ET during Poster Session B.

What is the title and abstract number for Nuvalent's NVL-330 poster (NUVL)?

Title: Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor; Abstract No. B057.

Where can attendees find Nuvalent's NVL-330 poster at the conference?

The poster is located in Exhibit Hall D at the AACR-NCI-EORTC conference in Boston.

Who is the presenter and corresponding author for the NVL-330 poster (NUVL)?

Yuting Sun is listed as the presenter and corresponding author.

Which session covers Nuvalent's NVL-330 preclinical intracranial activity data?

The data will be presented in Poster Session B on October 24, 2025.

Which investigators authored the NVL-330 abstract for Nuvalent (NUVL)?

Authors include Yuting Sun, Kristen L. Andrews, Anupong Tangpeerachaikul, Michael J. Walsh, Nancy E. Kohl, Joshua C. Horan, and Henry E. Pelish.